Antigens are central to immunoassays and IVD development. A key raw material decision is whether to use a native or recombinant antigen. Both work in ELISA, CLIA, and lateral flow, but differ in source, structure, batch consistency, and performance. This article compares the two and explains when native antigens are the better choice.
What is the difference between Recombinant and Native Antigens?
Antigens play an essential role in immunoassays, infectious disease testing, and the development of in vitro diagnostic (IVD) products. They are molecules or molecular structures recognized by the immune system and can trigger an immune response or be used as targets for antibody detection.
For diagnostic assay development, native antigens and recombinant antigens are two commonly used antigen types. Although both can serve as immunoreactive materials, they differ in their source, production process, molecular characteristics, consistency, and application. Understanding the differences between a recombinant antigen and a native antigen can help assay developers select the most appropriate raw material for ELISA, CLIA, lateral flow, and other immunoassay platforms.
What is Native Antigen?
Native antigen is an antigen obtained directly from its natural biological source, such as bacteria, viruses, cells, tissues, or other biological materials. Because native antigens are derived from their original source, they can retain structural characteristics, conformational epitopes, post-translational modifications, and other molecular features that may be difficult to reproduce using recombinant expression systems.
This can be particularly important when antibodies generated during natural infection recognize complex or conformational epitopes rather than a single linear protein sequence. However, obtaining native antigens can involve relatively complex extraction, purification, inactivation, and quality-control processes. Source materials may also introduce greater biological variability, making batch consistency, supply stability, and process control important considerations when selecting a native antigen supplier.
What is Recombinant Antigen?
Recombinant antigen is produced using genetic engineering technology. The gene encoding the target antigen is introduced into an appropriate expression system, such as E. coli, yeast, insect cells, or mammalian cells. The recombinant protein is then expressed, purified, and characterized for use in research or diagnostic applications.
A major advantage of recombinant antigens is their potential for scalable and controlled production. Once an appropriate expression and purification process has been established, recombinant antigens can provide relatively consistent production and help support large-scale assay development. However, the properties of a recombinant antigen can depend strongly on the selected expression system and purification strategy. Differences in protein folding, glycosylation, oligomerization, or other structural characteristics may affect antibody recognition and assay performance.
Recombinant vs Native Antigens: Key Differences
| Feature | Native Antigen | Recombinant Antigen |
| Source | Natural biological source | Genetically engineered expression system |
| Molecular characteristics | Closer to the naturally occurring antigen | Dependent on expression system |
| Epitope presentation | May retain complex or conformational epitopes | May differ from the native structure |
| Production | Extraction, purification, and processing | Gene expression and protein purification |
| Batch consistency | Requires strict source and process control | Generally easier to standardize |
| Scalability | May be limited by biological source | Generally highly scalable |
| Supply | Dependent on source availability | More controllable after process establishment |
| Application | Useful when native-like antigenicity is important | Suitable for many standardized immunoassays |
Why Choose a Native Antigen for IVD Assay Development?
One of the major reasons to consider a native antigen is its natural molecular structure and antigenic characteristics. Some diagnostic antibodies recognize epitopes that are influenced by protein folding, post-translational modifications, protein complexes, or other structural features. In these situations, a recombinant protein expressed in a heterologous system may not completely reproduce the antigenic profile of the naturally occurring target.
Common Challenges in Reagent Development
During your reagent development process, have you faced any of the following challenges?
· High development difficulty?
· Poor stability?
· High batch-to-batch variation?
· Difficult to scale up for mass production?
If so, we may have the solution you’ve been looking for.
Cnpair Native Antigens: High Activity, Full Traceability
Cnpair high-activity raw materials —— native antigens are suitable for the development and production of detection reagents for Mycoplasma pneumoniae (MP), Helicobacter pylori (HP), and others. They have now achieved stable mass production with full traceability and are compatible with multiple technology platforms, including lateral flow assays, chemiluminescence, and molecular diagnostics.
Why Choose Cnpair Native Antigens?
Native antigens can be particularly valuable when antibody recognition depends on native conformation, post-translational modifications, or complex epitopes. Cnpair native antigens are designed to meet these requirements and offer the following advantages:
 | Maintain native: conformation for higher bioactivity |
 | Full epitopes: Native antigens cover broader pathogen epitopes |
 | Multiple applications: Compatible with LF, CLIA and molecular platforms |
 | Robust compliance: BSL-2 Laboratory, ISO 13485 and ISO 9001 |
To support assay developers working with MP and HP, Cnpair offers the following native antigen products.
Mycoplasma pneumoniae (MP) Native Antigens: Large-scale production capacity: ≥ 5 L per batch
| Name | Type | Usage | Application |
|---|---|---|---|
| Mycoplasma antigen | Native antigen | Coating | LF |
| Mycoplasma antigen | Native antigen | Coating | EIA/CLIA |
| Anti Human IgM antibody | Secondary Ab | Ab Capture | EIA/CLIA/LF |
| Mycoplasma antigen | Ag | Control | EIA/CLIA/LF |
| Mycoplasma antigen | Ag | Nucleic Acid Control | qPCR |
Helicobacter pylori (HP) Native Antigens: Large-scale production capacity: ≥ 5 g per batch
| Name | Type | Usage | Application |
|---|---|---|---|
| HP antigen | Native antigen | Coating/Detecting | LF/CLIA/PETIA |
| Anti Human IgG antibody | Secondary Ab | Ab capture | LF/CLIA |
| HP antigen | Ag | Coating/Detecting | LF/CLIA/PETIA |
| HP antibody | Ab | Coating/Detecting | EIA/CLIA/LF |
| HP antigen | Ag | Control | EIA/CLIA/LF |
Chlamydia pneumoniae : Coming Soon
Looking for native antigens for your next IVD project? Contact Cnpair to discuss your target, assay platform, and raw material requirements.
FAQ
Native antigen is obtained directly from its natural biological source and may retain structural and antigenic characteristics of the original material.
Recombinant antigen is produced through genetic engineering using a suitable expression system.
Not necessarily. The appropriate antigen depends on the target, assay format, epitope requirements, and production needs.
Native antigens may better represent naturally occurring antigenic structures and can be useful when complex or conformational epitopes are important.
Cnpair provides native antigen and other IVD raw materials for diagnostic assay development and can support customers with different antigen and assay requirements.